Spectral AI announced that it has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study: University Medical Center, UMC, Burn Center at Texas Tech University Health Sciences Center led by principal investigator Alan Pang, M.D., Tampa General Hospital Burn Center led by principal investigator Jared Troy, M.D., and University of South Alabama, USA, Health Emergency Department led by Andrew Bright, D.O. These new locations expand the total number of U.S. Clinical Trial Sites to 16, comprised of both burn centers and Emergency Departments, EDs. The 2024 U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by Spectral AI’s DeepView System for burn indication. The study is expected to be the final clinical trial before the Company seeks FDA approval of its DeepView System for burn indication in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDAI:
- Spectral AI Adds Three New Clinical Trial Sites To Expedite Emergency Department Patient Enrollment
- Spectral AI initiated with a Buy at H.C. Wainwright
- Spectral AI Tackles Market Manipulation Concerns
- Spectral AI continues support of naked short selling inquiry
- Spectral AI Continues Support of Naked Short Selling Inquiry